Followers | 837 |
Posts | 120361 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Monday, April 30, 2007 1:02:30 AM
GTCB ReadMeFirst
[Miscellaneous additions and updates.]
What is GTC’s business all about?
#msg-15159486 The business model in a single sentence
#msg-17607391 Edited transcript from 3/5/07 conference call
#msg-9243634 Jan 2006 interview with CEO, Geoff Cox
#msg-9352093 2002 interview with Tom Newberry (dated, but still informative)
#msg-13171505 “Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals” (recommended for the technical reader)
#msg-17598322 Reference info on biogeneric/biosimilar drugs
#msg-17935613 Venn diagram of business model
#msg-15638633 Musings on business model (Dew)
Valuation and finances
#msg-17702024 Cash balance and 2007 cash-usage guidance
#msg-15309465 Share count for valuation purposes
#msg-17591547 Press release for 4Q06 results
#msg-17760532 Valuation comparator: Pharming
#msg-11037571 Valuation comparator: GlycoFi
#msg-19227430 What is a fair price?
Upcoming events
#msg-16969103 Clinical, preclinical goals in 2007-2008
#msg-17980761 Possible/probable news flow
Management and BoD
#msg-15702541 Composition of Board of Directors
#msg-19222735 Largest shareholders as of 4/5/07
#msg-18869318 Current insider holdings
#msg-18919535 Insider buying during past year
#msg-18432652 Recent executive hires
ATryn hereditary-deficiency program in Europe
#msg-11752181 Why ATryn?
#msg-11399356 ATryn approved by EMEA
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
#msg-14545343 HD sales projection
http://www.atiii.com What is hereditary AT deficiency? (simple)
http://tinyurl.com/yb9hl5 What is hereditary AT deficiency? (technical)
#msg-9502819 A patient’s story
Official product information:
#msg-11399033 (FAQ)
http://www.emea.eu.int/humandocs/PDFs/EPAR/atryn/058706en6.pdf
http://www.emea.eu.int/humandocs/PDFs/EPAR/atryn/H-587-PI-en.pdf
ATryn hereditary-deficiency program in U.S.
#msg-18463014 U.S. ATryn timeline
#msg-6543884 Limited availability of competing antithrombin
#msg-5607789 Efficacy endpoint is clinical DVT
#msg-5609005 Design of control arm
#msg-11410659 Likelihood of success
#msg-6632420 Patient eligibility and exclusions
#msg-11511614 Musings on a U.S. partnership
ATryn DIC/sepsis program
#msg-19225961 Scientific rationale for pursuing DIC/sepsis indication
#msg-16968800 How sepsis causes DIC
#msg-12483101 Existing therapeutic options are weak
#msg-12480578 Sepsis incidence is on the rise
#msg-16968788 Sepsis incidence is on the rise (addendum)
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
#msg-12511434 Phase-3 timeline
#msg-14495208 When will GTC receive milestone payments?
#msg-15305927 Design issues in the phase-2 trial
Other potential uses of ATryn
#msg-19225820 Reference list of abstracts and write-ups
#msg-19226464 How much product would be needed?
Risks and availability of plasma-derived proteins
#msg-17114738 Salient quote from CEO of ZymoGenetics
#msg-7306242 Which antithrombin will doctors prescribe?
#msg-4372780 Risks of plasma-derived proteins
#msg-17684473 Risks of plasma-derived proteins (addendum)
#msg-15535360 Risks of plasma-derived proteins (Mad Cow)
#msg-16098448 Limited supply of plasma-derived proteins
#msg-16098453 Limited supply of plasma-derived proteins (addendum)
GTC-LFB program in Factor VIIa (and other therapies)
#msg-13731860 Who is LFB?
#msg-13956439 Who is LFB? (addendum)
#msg-13708619 Partnership terms
#msg-15247168 How the collaboration works
#msg-16164190 Sky-high FVIIa price (rationale for GTC/LFB program);
everything you always wanted to know about FVIIa in practice
#msg-16645259 NovoSeven reaches blockbuster status
#msg-16968837 FVIIa sales projections
#msg-13763244 Patient pool for initial indication (hemophilia w/inhibitors)
#msg-14084250 NovoSeven for acquired hemophilia
#msg-13925693 NovoSeven for trauma
#msg-14921693 NovoSeven use in the military
Miscellaneous research and development programs
Capsule summaries: http://www.transgenics.com/products/prod.html
#msg-17933985 Pipeline timeline
#msg-19226889 Merrimack supply relationship
#msg-18566648 PharmAthene supply relationship
#msg-15170172 Background info on AAT deficiency
#msg-13797351 Grant for CD137 antibody program
#msg-7136629 Collaboration with Scancell
#msg-4316445 ATryn research contract with U.S. army
Intellectual property
#msg-9174865 Production (“milk”) patent
#msg-7179529 Purification patent
#msg-16887499 Pending patent applications
#msg-18949245 IP summary from most recent 10K report
#msg-18615705 Nuclear-transfer license from Geron
#msg-19226707 Notes on nuclear-transfer license
Existing and potential competition
(See GTC-LFB heading above for NovoSeven™ brand rFVIIa)
Plasma-derived products:
#msg-7221666 Price and availability of commercial plasma-derived AT
#msg-11909951 Thrombate AT from Talecris
#msg-15898317 Plasma-derived AT from Grifols
#msg-11829819 Talecris AAT
#msg-6488263 PurelyProteins AAT (market-size info)
#msg-14954548 Inhaled AAT from Kamada
Non-transgenic recombinant products:
#msg-14524596 Artisan Pharma thrombomodulin
#msg-14527640 Comments on Artisan’s program
#msg-15157973 Tifacogin for CAP/sepsis
#msg-14176380 AM-Pharma program in sepsis
#msg-14499024 AZN/Protherics program in sepsis
#msg-15573025 Lipoxen/Baxter program in clotting factors
#msg-18366299 Novo-Nordisk NN1731
#msg-17050443 DSM/Crucell antibody production
#msg-13600478 Protalix
http://greenovation.com Greenovation
Products derived from transgenic animals:
#msg-18396260 Roche / Therapeutic Human Polyclonals
#msg-16835174 Technical issues with transgenic chickens
#msg-16219066 Viragen / Oxford BioMedica (chickens)
#msg-16512199 Viragen admits it has a lot of work to do
#msg-7542154 Origen (chickens)
#msg-15899425 Kirin/Hematech (cows)
#msg-18894630 Argentine cows produce insulin
Products derived from transgenic plants:
#msg-18566945 Risks of plant-based platforms
#msg-15116312 Biolex (publication on homogeneity of glycosylation)
#msg-16610930 Biolex (Locteron)
#msg-5919466 Biolex (‘plantibody’ patent)
#msg-15925882 SemBioSys (plant-based insulin)
#msg-14191540 Prairie Plant Systems
Miscellaneous competition:
#msg-19221436 ATryn vs FXa inhibitors
#msg-13169472 GlycoFi/Merck (humanized yeast glycosylation)
#msg-13222976 More on the GlycoFi story
#msg-8863527 Companies to watch
Feature stories on GTCB and transgenics
#msg-17042733 Wired (2/14/07)
#msg-15920370 Managed Care (11/06)
#msg-13365243 Times of London (9/06)
#msg-13152292 Nature.com (9/06)
#msg-14278650 Biotechnology Healthcare (8/06)
#msg-12573463 Nature Biotechnology (8/06)
#msg-12273566 Boston Globe profiles Dr. Harry Meade (7/06)
#msg-11635041 Framingham, Mass. Daily News (6/06)
#msg-9243634 Red Herring (1/06)
#msg-9143261 Business Week (1/06)
#msg-8162424 Scientific American (11/05)
#msg-6806806 Wall St Transcript interview with Tom Newberry (6/05)
#msg-6775592 Newsweek special issue on healthcare (6/05)
#msg-6276428 Worcester, MA Telegram & Gazette (5/05)
#msg-7431316 Nature Biotechnology (10/04)
#msg-4057315 The Economist (9/04)
[Miscellaneous additions and updates.]
What is GTC’s business all about?
#msg-15159486 The business model in a single sentence
#msg-17607391 Edited transcript from 3/5/07 conference call
#msg-9243634 Jan 2006 interview with CEO, Geoff Cox
#msg-9352093 2002 interview with Tom Newberry (dated, but still informative)
#msg-13171505 “Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals” (recommended for the technical reader)
#msg-17598322 Reference info on biogeneric/biosimilar drugs
#msg-17935613 Venn diagram of business model
#msg-15638633 Musings on business model (Dew)
Valuation and finances
#msg-17702024 Cash balance and 2007 cash-usage guidance
#msg-15309465 Share count for valuation purposes
#msg-17591547 Press release for 4Q06 results
#msg-17760532 Valuation comparator: Pharming
#msg-11037571 Valuation comparator: GlycoFi
#msg-19227430 What is a fair price?
Upcoming events
#msg-16969103 Clinical, preclinical goals in 2007-2008
#msg-17980761 Possible/probable news flow
Management and BoD
#msg-15702541 Composition of Board of Directors
#msg-19222735 Largest shareholders as of 4/5/07
#msg-18869318 Current insider holdings
#msg-18919535 Insider buying during past year
#msg-18432652 Recent executive hires
ATryn hereditary-deficiency program in Europe
#msg-11752181 Why ATryn?
#msg-11399356 ATryn approved by EMEA
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
#msg-14545343 HD sales projection
http://www.atiii.com What is hereditary AT deficiency? (simple)
http://tinyurl.com/yb9hl5 What is hereditary AT deficiency? (technical)
#msg-9502819 A patient’s story
Official product information:
#msg-11399033 (FAQ)
http://www.emea.eu.int/humandocs/PDFs/EPAR/atryn/058706en6.pdf
http://www.emea.eu.int/humandocs/PDFs/EPAR/atryn/H-587-PI-en.pdf
ATryn hereditary-deficiency program in U.S.
#msg-18463014 U.S. ATryn timeline
#msg-6543884 Limited availability of competing antithrombin
#msg-5607789 Efficacy endpoint is clinical DVT
#msg-5609005 Design of control arm
#msg-11410659 Likelihood of success
#msg-6632420 Patient eligibility and exclusions
#msg-11511614 Musings on a U.S. partnership
ATryn DIC/sepsis program
#msg-19225961 Scientific rationale for pursuing DIC/sepsis indication
#msg-16968800 How sepsis causes DIC
#msg-12483101 Existing therapeutic options are weak
#msg-12480578 Sepsis incidence is on the rise
#msg-16968788 Sepsis incidence is on the rise (addendum)
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
#msg-12511434 Phase-3 timeline
#msg-14495208 When will GTC receive milestone payments?
#msg-15305927 Design issues in the phase-2 trial
Other potential uses of ATryn
#msg-19225820 Reference list of abstracts and write-ups
#msg-19226464 How much product would be needed?
Risks and availability of plasma-derived proteins
#msg-17114738 Salient quote from CEO of ZymoGenetics
#msg-7306242 Which antithrombin will doctors prescribe?
#msg-4372780 Risks of plasma-derived proteins
#msg-17684473 Risks of plasma-derived proteins (addendum)
#msg-15535360 Risks of plasma-derived proteins (Mad Cow)
#msg-16098448 Limited supply of plasma-derived proteins
#msg-16098453 Limited supply of plasma-derived proteins (addendum)
GTC-LFB program in Factor VIIa (and other therapies)
#msg-13731860 Who is LFB?
#msg-13956439 Who is LFB? (addendum)
#msg-13708619 Partnership terms
#msg-15247168 How the collaboration works
#msg-16164190 Sky-high FVIIa price (rationale for GTC/LFB program);
everything you always wanted to know about FVIIa in practice
#msg-16645259 NovoSeven reaches blockbuster status
#msg-16968837 FVIIa sales projections
#msg-13763244 Patient pool for initial indication (hemophilia w/inhibitors)
#msg-14084250 NovoSeven for acquired hemophilia
#msg-13925693 NovoSeven for trauma
#msg-14921693 NovoSeven use in the military
Miscellaneous research and development programs
Capsule summaries: http://www.transgenics.com/products/prod.html
#msg-17933985 Pipeline timeline
#msg-19226889 Merrimack supply relationship
#msg-18566648 PharmAthene supply relationship
#msg-15170172 Background info on AAT deficiency
#msg-13797351 Grant for CD137 antibody program
#msg-7136629 Collaboration with Scancell
#msg-4316445 ATryn research contract with U.S. army
Intellectual property
#msg-9174865 Production (“milk”) patent
#msg-7179529 Purification patent
#msg-16887499 Pending patent applications
#msg-18949245 IP summary from most recent 10K report
#msg-18615705 Nuclear-transfer license from Geron
#msg-19226707 Notes on nuclear-transfer license
Existing and potential competition
(See GTC-LFB heading above for NovoSeven™ brand rFVIIa)
Plasma-derived products:
#msg-7221666 Price and availability of commercial plasma-derived AT
#msg-11909951 Thrombate AT from Talecris
#msg-15898317 Plasma-derived AT from Grifols
#msg-11829819 Talecris AAT
#msg-6488263 PurelyProteins AAT (market-size info)
#msg-14954548 Inhaled AAT from Kamada
Non-transgenic recombinant products:
#msg-14524596 Artisan Pharma thrombomodulin
#msg-14527640 Comments on Artisan’s program
#msg-15157973 Tifacogin for CAP/sepsis
#msg-14176380 AM-Pharma program in sepsis
#msg-14499024 AZN/Protherics program in sepsis
#msg-15573025 Lipoxen/Baxter program in clotting factors
#msg-18366299 Novo-Nordisk NN1731
#msg-17050443 DSM/Crucell antibody production
#msg-13600478 Protalix
http://greenovation.com Greenovation
Products derived from transgenic animals:
#msg-18396260 Roche / Therapeutic Human Polyclonals
#msg-16835174 Technical issues with transgenic chickens
#msg-16219066 Viragen / Oxford BioMedica (chickens)
#msg-16512199 Viragen admits it has a lot of work to do
#msg-7542154 Origen (chickens)
#msg-15899425 Kirin/Hematech (cows)
#msg-18894630 Argentine cows produce insulin
Products derived from transgenic plants:
#msg-18566945 Risks of plant-based platforms
#msg-15116312 Biolex (publication on homogeneity of glycosylation)
#msg-16610930 Biolex (Locteron)
#msg-5919466 Biolex (‘plantibody’ patent)
#msg-15925882 SemBioSys (plant-based insulin)
#msg-14191540 Prairie Plant Systems
Miscellaneous competition:
#msg-19221436 ATryn vs FXa inhibitors
#msg-13169472 GlycoFi/Merck (humanized yeast glycosylation)
#msg-13222976 More on the GlycoFi story
#msg-8863527 Companies to watch
Feature stories on GTCB and transgenics
#msg-17042733 Wired (2/14/07)
#msg-15920370 Managed Care (11/06)
#msg-13365243 Times of London (9/06)
#msg-13152292 Nature.com (9/06)
#msg-14278650 Biotechnology Healthcare (8/06)
#msg-12573463 Nature Biotechnology (8/06)
#msg-12273566 Boston Globe profiles Dr. Harry Meade (7/06)
#msg-11635041 Framingham, Mass. Daily News (6/06)
#msg-9243634 Red Herring (1/06)
#msg-9143261 Business Week (1/06)
#msg-8162424 Scientific American (11/05)
#msg-6806806 Wall St Transcript interview with Tom Newberry (6/05)
#msg-6775592 Newsweek special issue on healthcare (6/05)
#msg-6276428 Worcester, MA Telegram & Gazette (5/05)
#msg-7431316 Nature Biotechnology (10/04)
#msg-4057315 The Economist (9/04)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.